文献速递外周动脉疾病

血管内碎石术治疗严重钙化股总动脉疾病:Disrupt PAD III观察性研究结果

Intravascular Lithotripsy for Treatment of Severely Calcified Common Femoral Artery Disease: Results From the Disrupt PAD III Observational Study.
PubMed 文献 · J Endovasc Ther · 2024-06-15

Disrupt PAD III观察性研究为前瞻性多中心注册研究,评估血管内碎石术(IVL)治疗钙化股总动脉(CFA)病变的急性安全性和有效性。177例CFA病变患者中163例可基于核心实验室数据分析,术后及最终残余狭窄分别为29.2±16.5%和23.6±11.5%,核心实验室评估未发现血管并发症。

要点

  • IVL治疗钙化CFA病变显示显著狭窄减少和良好的围手术期安全性。
  • 术后及最终残余狭窄分别为29.2±16.5%和23.6±11.5%。
  • 核心实验室评估无血管并发症,仅1例(0.8%)IVL后即刻出现限流性夹层。

核心结论

  • IVL治疗在严重钙化CFA病变中显示显著狭窄减少和良好的围手术期安全性。
  • 作者认为,对于不愿或高风险的血管外科手术患者,冲击波球囊血管成形术可作为外科治疗的替代选择。

研究设计与样本

  • Disrupt PAD III观察性研究(NCT02923193)为前瞻性多中心注册研究,评估IVL治疗钙化外周动脉疾病的急性安全性和有效性。
  • 177例患者有CFA治疗指征,其中163例可基于核心实验室数据分析,来自23个中心。
  • 164个治疗病变的特征包括中重度钙化95.1%、直径狭窄74.8±17.7%、病变长度53.6±53.1 mm。

主要发现

  • 32.3%的病变使用了伴随的钙修饰治疗。
  • 最终治疗包括药物涂层球囊68.9%和支架植入16.5%。
  • IVL术后和最终残余狭窄分别为29.2±16.5%和23.6±11.5%。
  • 核心实验室评估手术结束时无血管并发症(限流性夹层、穿孔、栓塞、慢血流或无复流、突然闭塞),仅1例(0.8%)在IVL治疗后即刻出现限流性夹层。

临床怎么用

  • 作者认为,冲击波球囊血管成形术可安全有效地治疗钙化CFA病变,具有高手术成功率和低并发症率,可作为不愿或高风险血管外科手术患者的替代选择。
  • 作者认为,该技术为临床医生提供了治疗钙化CFA病变的另一选择,且无动脉斑块旋切术相关的夹层、穿孔或远端栓塞风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical endarterectomy is currently considered the front-line therapy for the treatment of calcified lesions in the common femoral artery (CFA). Endovascular interventions have evolved, and their use is increasing in frequency. Intravascular lithotripsy (IVL) has shown promising safety and effectiveness in calcified CFA lesions in a small pilot study, but "real-world" evidence from a larger cohort is lacking. METHODS: The Disrupt PAD III Observational Study (NCT02923193) was a prospective, multicenter registry designed to assess the acute safety and effectiveness of IVL treatment for calcified peripheral arterial disease. Any concomitant treatment with other calcium-modifying technologies as well as definitive treatment strategies was at the discretion of the operators. Patients with CFA lesions were evaluated for acute angiographic safety and effectiveness outcomes following IVL treatment as determined by an independent angiographic core lab. RESULTS: Common femoral artery treatment was indicated in 177 patients (n=163 could be analyzed based on core-laboratory data) enrolled at 23 sites. Characteristics for 164 treated lesions included moderate-severe calcification 95.1%, diameter stenosis 74.8±17.7%, and lesion length 53.6±53.1 mm. Concomitant calcium-modifying therapy was used in 32.3% of lesions. Final therapy included drug-coated balloons in 68.9% and stenting in 16.5% of lesions. Post-IVL and final residual stenoses were 29.2±16.5%and 23.6±11.5%, respectively. No vascular complications (flow-limiting dissections, perforations, embolization, slow or no reflow, or abrupt closure) were present at the end of the procedure by core-laboratory assessment, with 1 (0.8%) flow-limiting dissection initially occurring immediately following IVL treatment. CONCLUSION: This study represents the largest real-world experience of IVL treatment in heavily calcified CFA lesions. Intravascular lithotripsy treatment showed significant stenosis reduction and favorable periprocedural safety in this challenging patient population.Clinical ImpactIn this study we show that calcified common femoral artery disease can be safely and effectively treated with shockwave balloon angioplasty with high procedural success and low complication rates and in clinical practice can now be offered as an alternative to surgical treatment in those patients reluctant to or high risk for vascular surgery. This opens another option for clinicians to treat calcified common femoral artery disease without the risk of dissection, perforation or distal embolization that are associated with atherectomy. This study shows that shockwave lithoplasty offers an innovative plaque modification technology to tackle calcified disease in the common femoral artery.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Shammas NW, Mangalmurti S, Bernardo NL, et al. Intravascular Lithotripsy for Treatment of Severely Calcified Common Femoral Artery Disease: Results From the Disrupt PAD III Observational Study. J Endovasc Ther. 2024. PMID: 38877777. doi:10.1177/15266028241255622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。